Conformis,Inc. (NASDAQ:CFMS) Files An 8-K Entry into a Material Definitive Agreement
Item 8.01

Entry into a Material Definitive Agreement

The information set forth in Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference in this Item 8.01.

On December 13, 2018, Conformis, Inc. (the “Company”) entered into a Fifth Amendment (the “Amendment”) to the Loan and Security Agreement dated January 6, 2017 (as previously amended, the “Loan and Security Agreement”) with Oxford Finance LLC (“Oxford”).

The Amendment, among other things, reduces the revenue milestones under the Loan and Security Agreement that apply beginning in January 2019, grants the Company the option to prepay $15 million of the $30 million in term loans advanced under the Loan and Security Agreement and reduces the Company’s restricted cash covenant to $5 million.

Except as modified by the Amendment, all terms and conditions of the Loan and Security Agreement remain in full force and effect. A copy of the Amendment is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

On December 13, 2018, the Company prepaid $15 million aggregate principal amount of the $30 million in term loans under the Loan and Security Agreement, together with accrued and unpaid interest thereon and a pro rata prepayment fee.

On December 13, 2018, the Company issued a press release announcing certain business updates.

The Company announced it plans to continue to execute its new product development programs focusing on the Conformis Hip System, iTotal G3 and cementless Press Fit knee. In the second half of 2019, the Company expects to achieve full commercial launch of its Conformis Hip System, as well as the limited commercial release of its iTotal G3 total knee. The Company also remains on track to deliver the limited commercial release of its cementless knee offering in early 2020.

The Company has selectively identified opportunities to expand its distribution in certain international markets. The expansion into other international markets is intended to help offset the sales weakness the Company is experiencing in Germany.

In December 2018, the Company reduced its personnel base, resulting in a reduction of approximately 10% of its total workforce. The Company expects to incur employee severance charges and other exit costs of approximately $700,000 in the fourth quarter of 2018 and generate annual personnel expense savings in excess of $4 million in 2019.

Cautionary Statement Regarding Forward-Looking Statements

Statements in this Current Report on Form 8-K about the Company’s future expectations, plans and prospects, including statements about the anticipated timing of its product launches, and its financial position and results, ability to achieve profitability, total revenue, product revenue, gross margin, operations and operating expenses, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. The Company may not actually achieve the forecasts disclosed in its forward-looking statements, and undue reliance should not be placed on forward-looking statements. Actual financial results could differ materially from the projections disclosed in the forward-looking statements made by the Company as a result of a variety of risks and uncertainties, including whether the Company’s cash resources will be sufficient to fund its continuing operations for the periods anticipated; risks related to the Company’s estimates and expectations regarding its revenue, gross margin, expenses, revenue growth and other results of operations; risks related to the impact of the Company’s reduction in force; risks associated with the Company’s ability or inability to satisfy loan covenants; and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this Current Report on Form 8-K represent the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments may cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

Conformis Inc Exhibit
EX-10.1 2 ex_fifthamendment.htm EXHIBIT 10.1 Exhibit Exhibit 10.1FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENTTHIS FIFTH AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of December 13,…
To view the full exhibit click here

About Conformis,Inc. (NASDAQ:CFMS)

ConforMIS, Inc. is a medical technology company that uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants. The Company’s products include iTotal CR, which is the cruciate-retaining, customized total knee replacement system to restore the natural shape of a patient’s knee; iTotal PS, which is the posterior cruciate ligament substituting, or posterior-stabilized, customized total knee replacement product to restore the natural shape of a patient’s knee; iDuo, which is the customized bicompartmental knee replacement system, and iUni, which is the customized unicompartmental knee replacement product for treatment of the medial or lateral compartment of the knee. Its iFit technology platform comprises three elements: iFit Design, iFit Printing and iFit Just-in-Time Delivery. The Company markets and sells its products in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Singapore and Hong Kong.